August 2024: The United States Food and Drug Administration (FDA) awarded fast approval late last week to the immunotherapy afamitresgene autoleucel (afami-cel) for the treatment of adults with synovi...
tumor-infiltrating-lymphocyte-therapy
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or met...
tumor-infiltrating-lymphocyte-therapy